The fiscal year 2015/16 was significantly influenced by the IPO in February 2016 with its related costs and one-off effects as well as by partly difficult market developments. Nonetheless, the company continues to expect the EBIT break-even to be achieved as planned in fiscal year 2017/18.
The Management Board is still satisfied with the past financial year: „The successful course of our IPO shows that the bioeconomy is accepted and understood as a future-oriented topic and is also indisputably recognized in capital market circles as a future sector. It is our aim to establish BRAIN long-term and sustainably as a substantial market participant of the bio-based economy“, says Jürgen Eck, CEO of BRAIN AG.
For many years, BRAIN has been reporting on the company’s work in quarterly reports which have won multiple communications and design awards. In addition to the audited group financials and discussions, the BRAIN annual report, entitled “Engineering Biology”, also provides exciting insights into the world of biodiversity, BRAIN’s own BioArchive, the product pipeline, more detailed information on the strategic partnerships and selected programs of the BRAIN-Group, as well as a summary of the highlights of the financial year.
The annual report can now be accessed at www.brain-biotech.de/en/investor-relations/financial-publications. Upon request, a printed copy can be sent by post as soon as it is available.